drugset
drugset / Trial / NCT05953506

Phase 1a Study in Healthy Participants

NCT05953506 ↗

Phase 1 Unknown 52 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral HS-10506 in Chinese Healthy Subjects.

Timeline

Start
2023-07-17
Primary completion
2023-12-24
Completion
2023-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10506 Unknown — Oral

Indications

No indication recorded.